Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02856425
Title Trial Of Pembrolizumab And Nintedanib (PEMBIB)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

Advanced Solid Tumor

thymic carcinoma

lung adenocarcinoma

cervical squamous cell carcinoma

lung squamous cell carcinoma

renal cell carcinoma

hepatocellular carcinoma

transitional cell carcinoma

malignant mesothelioma

Therapies

Nintedanib + Pembrolizumab

Age Groups: senior | adult
Covered Countries


No variant requirements are available.